Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Centessa Pharmaceuticals Plc ADR
(NQ:
CNTA
)
13.48
-0.02 (-0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
327,480
Open
13.36
Bid (Size)
13.25 (1)
Ask (Size)
13.50 (2)
Prev. Close
13.50
Today's Range
13.26 - 13.90
52wk Range
5.150 - 14.48
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
August 27, 2024
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Performance
YTD
+67.87%
+67.87%
1 Month
+26.57%
+26.57%
3 Month
+67.66%
+67.66%
6 Month
+29.12%
+29.12%
1 Year
+100.00%
+100.00%
More News
Read More
CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
August 13, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
June 10, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 21, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
May 13, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
April 23, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
April 23, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
April 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023
March 28, 2024
Via
InvestorPlace
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
March 28, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
Via
InvestorPlace
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
February 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 09, 2024
Via
Benzinga
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
February 09, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
January 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
December 13, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
December 10, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
November 27, 2023
Via
Benzinga
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
November 27, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
November 13, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.